| 0.2851 -0.065 (-18.5%) | 03-24 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Midatech Pharma plc is a pharmaceutical company focused on the research and development of drug delivery technologies and therapeutic solutions across the United Kingdom, Europe, and international markets. Its active pipeline includes MTX110, an investigational direct-delivery treatment for aggressive brain tumors such as diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. Also in development are MTX114, a topical immunosuppressant for managing psoriasis; MTD211, an extended-release formulation of brexpiprazole for schizophrenia and as an adjunct for major depressive disorder; and MTD219, a long-acting version of tacrolimus designed to mitigate the risk of organ transplant rejection. The company also leverages proprietary drug delivery platforms: Q-Sphera, a polymer microsphere microtechnology for sustained drug release; MidaSolve, an oligosaccharide nanotechnology enabling the solubilization and direct, localized liquid administration of drugs into tumors; and MidaCore, a gold nanoparticle system engineered for targeted delivery of chemotherapeutic or immunotherapeutic agents to disease sites. Founded in 2000, Midatech Pharma plc is headquartered in Cardiff, United Kingdom.
Thu, 25 Apr 2024
Midatech Pharma PLC (NASDAQ: MTP) - Share Price - intelligentinvestor.com.au
Mon, 17 Oct 2022
Midatech Pharma PLC Announces Receipt of NASDAQ Notification - Yahoo Finance
Mon, 21 Jun 2021
Stocks to Buy: Shares That May See a Big Short Squeeze This Week: Fintel - Business Insider
Wed, 02 Dec 2020
Midatech Pharma Stock Price Forecast. Should You Buy MTP? - StockInvest.us
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|